Clinical trial NCT04723303: Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
Official title: Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Polymyositis
Dermatomyositis
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: Restem, LLC.
First posted: 2021-01-25
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Study Participants will be assigned to one of 3 doses of stem cells depending on when the subject is enrolled. The first three patients will be assigned to the low dose group, the next three patients will be assigned the intermediate dose group and last three patients will receive the high dose of ULSC's. An independent review group will evaluate the response to therapy to each dose group before moving to the next dose. The groups and doses are described below:

A low dose group receives an IV infusion of 50 million stem cells.

An intermediate dose group receives an IV infusion of 100 million stem cells.

A high dose group receives an IV infusion of 200 million stem cells.
Primary purpose: TREATMENT

Brief summary: This study will investigate Umbilical Cord Lining Stem Cells (ULSC) as an investigational medicinal product and its use in patients with polymyositis (PM) or dermatomyositis (DM) to see if a single intravenous (IV) infusion of allogeneic umbilical cord lining stem cells (ULSC) safe, tolerable, and feasible to administer.


Eligibility criteria: Inclusion Criteria:

1. Adult, male or female, age ≥18 years old
2. Diagnosis of definite or probable DM or PM, according to the criteria of Bohan and Peter
3. Patients with PM will either be positive for a myositis-associated antibody or have undergone evaluation to exclude mimics, as deemed appropriate by the Investigator (See Note below).
4. Signs informed consent.

Exclusion Criteria:

1. A diagnosis of inclusion body myositis, juvenile DM or PM, myositis in the context of significant overlap with another systemic autoimmune rheumatologic disease.
2. Non immune myopathies.
3. Cancer associated myositis.
4. Hypersensitivity to study product components. History of hypersensitivity to dimethyl sulfoxide (DMSO).
5. Pregnant or lactating women.
6. Concomitant severe cardiac, pulmonary disease, active infection or other conditions that preclude assessment of safety and efficacy of the study product.
7. Patients with predominant muscle atrophy secondary to uncontrolled or chronic DM or PM, based on clinical, biochemical, and/or radiologic assessment, despite previous optimized treatment.
8. Anticipated need for surgery during the trial period.
9. A history of prevalent noncompliance with medical therapy.
10. Recipient of an organ transplant.
11. Neutropenia (absolute neutrophil count\<1,800/mm3 \[or \<1,000/mm3 in African-American subjects\]).
12. Severe impairment in renal function (estimated glomerular filtration rate \<30 ml/kg\*min).
13. Recent or planned use of vaccination with live attenuated viruses.
14. Active cancer or prior diagnosis of cancer within the past 2 years (patients with basal and squamous cell cancer of skin will not be excluded).
15. Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition.
16. Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up.
17. History of Atrial septal defect or ventricular septal defect

Primary outcomes:
measure: Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.
timeFrame: Within 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Carl Pepine, MD
role: PRINCIPAL_INVESTIGATOR
References: